Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB-3403 in Healthy Volunteers and Subjects With Elevated LDL-C
NCT06239714Phase 1Not yet recruiting
- Sponsor
- SanegeneBio
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
01
Overview
Phase 1, randomised, double-blind trial of SGB-3403 in hyperlipidemia (6 arms), sponsored by SanegeneBio. Primary endpoints: Number of participants with adverse events at 169 days and Number of participants with abnormal laboratory tests results at 169 days. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
SGB-3403
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06239714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239714.